Abstract
Plants have great potential as photosynthetic factories to produce pharmaceutically important and commercially valuable biomedicines and industrial proteins at low cost. The U.S. Food and Drug Administration (U.S. FDA) has approved the drug Elelyso (taliglucerase alfa) produced by carrot cells for treatment of type 1 Gaucher’s disease in 2012. The commercial potential of biomedicines produced by molecular farming has dramatically improved due to the success of an experimental drug called ZMapp, which has immunological activity in Ebola patients. A cocktail of three monoclonal antibodies was produced in tobacco (Nicotiana benthamiana) plants (Chen and Davis 2016). At present, very few drugs made by this technology have been approved by worldwide authorities such as the U.S. FDA. However, plants have been proposed as a novel paradigm for commercial production of proteins over the next decade. In recent years, leading researchers on molecular farming have given more priority to the area of animal-free therapeutic proteins such as parenteral and oral vaccines. Although plant-based platforms have considerable advantages over traditional systems such as bacterial and animal systems, there are several obstacles to commercial-scale production, especially with regards to improving the quality and quantity of plant-produced biologics and industrial materials. One of the biggest barriers to commercialization of this technology is the intense scrutiny of these new plant varieties by regulatory agencies and the public as well as the high costs associated with their regulatory approval.
Article PDF
Similar content being viewed by others
References
Abiri R, Valdiani A, Maziah M, Shaharuddin NA, Sahebi M, Yusof ZNB, Atabaki N, Tale D (2015) A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Curr Issues Mol Biol 18:21–42
Bakker H, Rouwendal GJ, Karnoup AS, Florack DE, Stoopen GM, Helsper JP, van Ree R, van Die I, Bosch D (2006) An antibody produced in tobacco expressing a hybrid b-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes. Proc Natl Acad Sci USA 103:7577–7582
Broz A, Huang N, Unruh G (2013) Plant-based protein biomanufacturing. Genetic Engineering & Biotechnology News: FEB15
Chen Q, Davis KR (2016) The potential of plants as a system for the development and production of human biologics. 5(F1000 Faculty Rev):912 (doi:10.12688/f1000research.8010.1)
Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, Moldovan-Loomis C, Srinivasan M, Cuison S, Cardarelli PM, Dickey LF (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591–1597
Dugdale B, Mortimer CL, Kato M, James TA, Harding RM, Dale JL (2013) In plant activation: an inducible, hyperexpression platform for recombinant protein production in plants. Plant Cell 25:2429–2443
Farran I, Sánchez-SerranoJJ, Medina JF, Prieto J, Mingo-Castel AM (2002) Targeted expression of human serum albumin to potato tubers. Transgenic Res 11:337–346
Faye L, Boulaflous A, Benchabane M, Gomord V, Michaud D (2005) Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming. Vaccine 23:1770–1778
Fischer R, Schillberg S, Buyel JF, Twyman RM (2013) Commercial aspects of pharmaceutical protein production in plants. Curr Pharm Des 19:5471–5477
Gleba Y, Klimyuk V, Marillonnet S (2007) Viral vectors for the expression of proteins in plants. Curr Opin Biotech 18:134–141
Healy M (2014) U.S. seeks to speed up production of Ebola drug. LA Times 2014.9.2
Hefferon KL (2012) Plant virus expression vectors set the stage as production platforms for biopharmaceutical proteins. Virology 433:1–6
Hood EE (2002) From green plants to industrial enzymes. Enzyme Microb Tech 30:279–283
Hood EE, Howard JA (2014) Commercial plant-produced recombinant avidin. In JA Howard, EE Hood, eds. Commercial plantproduced recombinant protein products. Springer, London, pp 15–25
Howard JA, Christon P (2014) Introduction: Plant-produced protein products. In JA Howard, EE Hood, eds. Commercial plantproduced recombinant protein products. Springer, London, pp 1–11
Jouzani GS, Tohidfar M (2013) Plant molecular farming: Future prospects and biosafety challenges. Biosafety 2: e136. doi: 10.4172/2167-0331.1000e136
Lee SW (2010) Current status on the development and commercialization of GM plants. J Plant Biotechnol 37:305–312
Lyon K (2016) LeafBio announces conclusion of ZMapp™ clinical Trial. Therapy to treat ebola shows promise. Press release, Mapp Biopharmaceutical, Inc.
MacDonald J, Doshi K, Dussault M, Hall JC, Holbrook L, Jones G, Kaldis A, Klima CL, Macdonald P, McAllister T, McLean MD, Potter A, Richman A, Shearer H, Yarosh O, Yoo HS, Topp E, Menassa R (2015) Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles. Biotechnol Adv 33:1572–1581
Malabadi RB, Chalannavar RK, Meti NT, Gani RS, Vijayakumar S, Mulgund SS, Masti S, Chougale R, Odhav B, Sowmyashree K, Supriya S, Nityasree BR, Divakar MS (2016) Insulin plant, costus speciosus: ethnobotany and pharmacological updates. Int J Curr Res Biosci Plant Biol 3:151–161
Paul M, Ma JKC (2011) Plant-made pharmaceuticals: Leading products and production platforms. Biotechnol Appl Bioc 58:58–67
Paul MJ, Thangaraj H, Ma JK (2015) Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector. Plant Biotechnol J 13:1209–1920
Rosales-Mendoza S, Angulo C, Meza B (2016) Food-grade organisms as vaccine biofactories and oral delivery vehicles. Trends Biotechnol 34:124–136
Rybicki EP, Chikwamba R, Koch M, Rhodes JI, Groenewald JH (2012) Plant-made therapeutics: an emerging platform in South Africa. Biotechnol Adv 30:449–459
Sack M, Hofbauer A, Fischer R, Stoger E (2015) The increasing value of plant-made proteins. Curr Opin Biothech 32:163–170
Shaaltiel Y, Bartfeld D, Hashmueli S, Baum S, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 5:579–590
Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, Kushnir N, Sharma S, Yusibov V (2011) Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 7:41–50
Sparrow P, Broer I, Hood EE, Eversole K, Hartung F, Schiemann J. (2013) Risk assessment and regulation of molecular farming -a comparison between Europe and US. Curr Pharm Des 19:5513–5530
Strasser R, Altmann F, Steinkellner H (2014) Controlled glycosylation of plant-produced recombinant proteins. Curr Opin Biothech 30:95–100
Sylvester AW, Lewis RV, David Jackson D (2011) Patent No. U.S. 8993844 B1 Production of spider silk protein in corn
Topp E, Irwin R, McAllister T, Lessard M, Joensuu JJ, Kolotilin I, Conrad U, Stöger E, Mor T, Warzecha H, Hall JC, McLean MD, Cox E, Devriendt B, Potter A, Depicker A, Virdi V, Holbrook L, Doshi K, Dussault M, Friendship R, Yarosh O, Yoo HS, MacDonald J, Menassa R (2016) The case for plant-made veterinary immunotherapeutics. Biotechnol Adv 34:597–604
Tschofen M, Knopp D, Hood E, Stoge E (2016) Plant molecular farming: Much more than medicines. Annu Rev Anal Chem 9:271–294
Tusé D, Tu T, McDonald KA (2014) Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes. Biomed Res Int, http://dx.doi.org/10.1155/2014/256135
Twyman RM, Stöger E, Schillberg S, Christou P, Fischer R (2003) Molecular farming in plants: host systems and expression technology. Trends Biotechnol 21:570–578
Wang YC, Peterson SE, Loring JF (2014) Protein post-translational modifications and regulation of pluripotency in human stem cells. Cell Res 24:143–160
Werner S, Breus O, Symonenko Y, Marillonnet S, Gleba Y (2011) High-level recombinant protein expression in transgenic plants by using a double-inducible viral vector. Proc Natl Acad Sci USA 108:14061–14066
Xu J, Dolan MC, Medrano G, Cramer CL, Weathers PJ (2012) Green factory: Plants as bioproduction platforms for recombinant proteins. Biotechnol Adv 30:1171–1184
Yamanaka T, Ohta T, Takahashi M, Meshi T, Schmidt R, Dean C, Naito S, Ishikawa M (2000) TOM1, an Arabidopsis gene required for efficient multiplication of a tobamovirus, encodes a putative transmembrane protein. Proc Natl Acad Sci USA 97:10107–10112
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, K.Y., Wi, S.J. Potential of plants to produce recombinant protein products. J. Plant Biol. 59, 559–568 (2016). https://doi.org/10.1007/s12374-016-0482-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12374-016-0482-9